Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tsuji

Showing results (501-510 of 515) with videos related to

Pageof 52
Sort By:
Nature Genetics|January 23, 1999
Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporterJ Nezu, I Tamai, A Oku, et al.
ESMO Open|May 7, 2025
Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13ARK Ouchi, Y Sunakawa, A Tsuji, et al.
The Pharmacogenomics Journal|October 5, 2016
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trialsA Sebio, S Stintzing, V Heinemann, et al.
British Journal of Cancer|April 17, 2015
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patientsW Ichikawa, K Uehara, K Minamimura, et al.
ESMO Open|September 13, 2023
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16H Yasui, Y Okita, M Nakamura, et al.
British Journal of Cancer|January 13, 2017
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancerT Ioka, Y Komatsu, N Mizuno, et al.
Cell Reports|May 3, 2018
Role of Selenof as a Gatekeeper of Secreted Disulfide-Rich GlycoproteinsSun Hee Yim, Robert A Everley, Frank A Schildberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2014
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancerY Yamada, K Higuchi, K Nishikawa, et al.
The Biochemical Journal|May 22, 2016
Selenophosphate synthetase 1 is an essential protein with roles in regulation of redox homoeostasis in mammalsRyuta Tobe, Bradley A Carlson, Jang Hoe Huh, et al.
The Journal of Biological Chemistry|July 20, 2011
Roles of the 15-kDa selenoprotein (Sep15) in redox homeostasis and cataract development revealed by the analysis of Sep 15 knockout miceMarina V Kasaikina, Dmitri E Fomenko, Vyacheslav M Labunskyy, et al.
Pageof 52

Showing results (501-510 of 515) with videos related to

Sort By:
Pageof 52
Nature Genetics|January 23, 1999
Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporterJ Nezu, I Tamai, A Oku, et al.
ESMO Open|May 7, 2025
Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13ARK Ouchi, Y Sunakawa, A Tsuji, et al.
The Pharmacogenomics Journal|October 5, 2016
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trialsA Sebio, S Stintzing, V Heinemann, et al.
British Journal of Cancer|April 17, 2015
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patientsW Ichikawa, K Uehara, K Minamimura, et al.
ESMO Open|September 13, 2023
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16H Yasui, Y Okita, M Nakamura, et al.
British Journal of Cancer|January 13, 2017
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancerT Ioka, Y Komatsu, N Mizuno, et al.
Cell Reports|May 3, 2018
Role of Selenof as a Gatekeeper of Secreted Disulfide-Rich GlycoproteinsSun Hee Yim, Robert A Everley, Frank A Schildberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2014
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancerY Yamada, K Higuchi, K Nishikawa, et al.
The Biochemical Journal|May 22, 2016
Selenophosphate synthetase 1 is an essential protein with roles in regulation of redox homoeostasis in mammalsRyuta Tobe, Bradley A Carlson, Jang Hoe Huh, et al.
The Journal of Biological Chemistry|July 20, 2011
Roles of the 15-kDa selenoprotein (Sep15) in redox homeostasis and cataract development revealed by the analysis of Sep 15 knockout miceMarina V Kasaikina, Dmitri E Fomenko, Vyacheslav M Labunskyy, et al.
Pageof 52